Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin A vs Placebo for Myofascial Pain Disorder
NCT03223298Phase 3Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2018
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myofascial pain syndrome (MPS) comparing Botulinum Toxin Type A with Placebo (2 arms). Primary endpoint: Change in Jaw Pain as Reported by Patient on Visual Analog Scale at 3 months. Started Aug 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
myofascial pain syndrome (MPS)
Beyond the preview
Go deeper on NCT03223298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223298.